Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Position Lowered by Eagle Global Advisors LLC

Eagle Global Advisors LLC lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.1% in the 1st quarter, Holdings Channel reports. The fund owned 21,499 shares of the medical research company’s stock after selling 24 shares during the period. Eagle Global Advisors LLC’s holdings in Thermo Fisher Scientific were worth $10,698,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Bernard Wealth Management Corp. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $25,000. Ameriflex Group Inc. purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $30,000. IMA Advisory Services Inc. purchased a new stake in Thermo Fisher Scientific in the 1st quarter worth approximately $35,000. Navigoe LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in Thermo Fisher Scientific in the 1st quarter worth approximately $37,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research analyst reports. Argus cut their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a research report on Tuesday, April 29th. Raymond James Financial reiterated an “outperform” rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research report on Thursday, July 24th. Royal Bank Of Canada dropped their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Finally, Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Seven analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $593.00.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 8,000 shares of the business’s stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $454.45, for a total value of $3,635,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $52,340,824.30. The trade was a 6.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,400 shares of company stock worth $8,345,792. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $461.34 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market capitalization of $174.21 billion, a price-to-earnings ratio of 26.68, a P/E/G ratio of 2.46 and a beta of 0.74. The company’s fifty day moving average is $426.80 and its two-hundred day moving average is $462.63. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period last year, the business posted $5.37 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.